All In Biotech

Drug Trial Radar · NCT01367249

Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery

Efficacy and Safety of Bromfenac Ophthalmic Solution vs. Placebo for the Treatment of Ocular Inflammation and Pain Associated With Cataract Surgery.

Last checked: Nov 20, 2026Latest source record: May 6, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 440 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

440

Actual

Start

May 2011

Primary completion

Jul 2011

Study completion Dec 2011

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedIndustry
Sponsor type
Industry
First posted
Jun 7, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an efficacy study of Bromfenac Ophthalmic Solution in cataract surgery.

Conditions

  • Pain
  • Inflammation
  • Cataract

Interventions

  • Bromfenac Ophthalmic SolutionDrug

    Sterile ophthalmic solution

  • PlaceboDrug

    Sterile ophthalmic solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ocular InflammationTime frame: Day 15

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ISTA Pharmaceuticals, Inc.

    Irvine, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.